featured
Brigatinib vs Crizotinib in Advanced ALK Inhibitor–Naïve ALK-Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
J. Clin. Oncol 2020 Aug 11;[EPub Ahead of Print], DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, A Delmonte, MR García Campelo, DW Kim, F Griesinger, E Felip, R Califano, A Spira, SN Gettinger, M Tiseo, HM Lin, N Gupta, MJ Hanley, Q Ni, P Zhang, S PopatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.